Natalizumab biosimilar (Polpharma Biologics)

那他珠单抗生物类似药 (Polpharma Biologics)

Report date: 2025/02/10 15:37:08

Base Information

Drug NameNatalizumab biosimilar (Polpharma Biologics)
Drug Alias NameNatalizumab-sztnTyrukoPB-006DST-356A1
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Biosimilar
Mechanisms of ActionIntegrin alpha-4/beta-1 antagonistsIntegrin alpha-4/beta-7 antagonists
TargetsIntegrin alpha-4/beta-1Integrin alpha-4/beta-7
Therapy Area/IndicationsMultiple Sclerosis, Relapsing-RemittingMultiple SclerosisCrohn Disease
Global Approved IndicationsMultiple Sclerosis, Relapsing-RemittingMultiple SclerosisCrohn Disease
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2023/08/24
Country/TerritoryUnited StatesUkrainePoland +[10] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesPolpharma Biologics Sa
China Registration ClassN/A

Develop Information

Active CompaniesPolpharma Biologics SaSandoz AgSandoz Inc +[5] 
Inactive CompaniesN/A
Active IndicationsMultiple Sclerosis, Relapsing-RemittingMultiple SclerosisCrohn Disease
Inactive IndicationsN/A

Other Information

ATC CodeL04AG03
Related LinksN/A